[go: up one dir, main page]

BR9812127A - Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase - Google Patents

Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase

Info

Publication number
BR9812127A
BR9812127A BR9812127-8A BR9812127A BR9812127A BR 9812127 A BR9812127 A BR 9812127A BR 9812127 A BR9812127 A BR 9812127A BR 9812127 A BR9812127 A BR 9812127A
Authority
BR
Brazil
Prior art keywords
cox
inhibitors
prostaglein
endoperoxide
cyclooxygenase
Prior art date
Application number
BR9812127-8A
Other languages
Portuguese (pt)
Inventor
Lawrence A Black
Anwer Basha
Teodozyjkolasa
Michael E Kort
Huaqing Liu
Catherine M Mccarty
Meena V Patel
Jeffrey J Rohde
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR9812127A publication Critical patent/BR9812127A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"ARILPIRIDAZINONAS COMO INIBIDORES DA BIOSSìNTESE DE PROSTAGLEINA ENDOPERóXIDO H SINTASE" A presente invenção divulga compostos de piridazinona, os quais são inibidores da ciclooxigenase (COX) e, em particular, são inibidores seletivos da ciclooxigenase-2 (COX/2). A COX-2 é a isoforma capaz de ser induzida associada com a inflamação, em oposição à isoforma constitutiva, a ciclooxigenase-1 (COX-1), que é uma enzima "zeladora" importante em muitos tecidos, incluindo o trato gastrointestinal (GI) e os rins. A seletividade destes compostos para a COX-2 minimiza os efeitos colaterais GI e renais não desejados, vistos com as drogas antiinflamatórias não-esteroidais (NSAIDs) atualmente vendidas."ARYLYPYRIDAZINES AS INHIBITORS OF PROSTAGLEIN ENDOPEROXIDE H SYNTHESIS BIOSYNTHESIS" The present invention discloses pyridazinone compounds, which are inhibitors of cyclooxygenase (COX) and, in particular, are selective inhibitors of cyclooxygenase-2 (COX / 2). COX-2 is the isoform capable of being induced associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "janitor" enzyme in many tissues, including the gastrointestinal tract (GI ) and the kidneys. The selectivity of these compounds for COX-2 minimizes unwanted GI and renal side effects, seen with the currently sold non-steroidal anti-inflammatory drugs (NSAIDs).

BR9812127-8A 1997-08-22 1998-08-10 Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase BR9812127A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91702397A 1997-08-22 1997-08-22
PCT/US1998/016479 WO1999010331A1 (en) 1997-08-22 1998-08-10 Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
BR9812127A true BR9812127A (en) 2000-07-18

Family

ID=25438243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812127-8A BR9812127A (en) 1997-08-22 1998-08-10 Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase

Country Status (8)

Country Link
EP (1) EP1007515A1 (en)
BR (1) BR9812127A (en)
CA (1) CA2299300C (en)
CO (1) CO4970740A1 (en)
SA (1) SA98190764B1 (en)
TW (1) TWI232216B (en)
WO (1) WO1999010331A1 (en)
ZA (1) ZA987555B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6525053B1 (en) * 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
NZ504045A (en) 1997-11-19 2001-06-29 Kowa Co Pyridazine derivatives with inhibitory action against interleukin-1-beta production
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
EP1130015A4 (en) * 1998-08-14 2006-02-08 Nihon Nohyaku Co Ltd Pyridazinone derivatives
HK1041876B (en) * 1998-10-27 2006-06-23 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2000247959A (en) 1999-02-26 2000-09-12 Kowa Co Pyridazin-3-one derivatives and pharmaceuticals containing the same
IL144760A0 (en) 1999-12-08 2002-06-30 Pharmacia Corp Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
JP2003523958A (en) 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド Inhibitors, compositions and uses of nitrosated and nitrosylated cyclooxygenase-2
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
ITMI20010733A1 (en) 2001-04-05 2002-10-05 Recordati Chem Pharm USE OF ISOENZIN COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE
AR038957A1 (en) 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
JP2005519895A (en) * 2002-01-18 2005-07-07 ファルマシア・コーポレーション Substituted pyridazinones as P38 inhibitors
US7211598B2 (en) 2002-06-28 2007-05-01 Nitromed, Inc. Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US7211577B2 (en) 2003-03-18 2007-05-01 Kowa Co., Ltd. Water-soluble phenylpyridazine derivative and medicine containing the same
ES2275218T3 (en) 2003-05-07 2007-06-01 Osteologix A/S HYDROSOLUBLE STRONTIUM SALTS FOR THE TREATMENT OF CARTILAGOS AND / OR BONE AFFECTIONS.
WO2005007632A1 (en) * 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
DE602005014359D1 (en) 2004-06-09 2009-06-18 Sumitomo Chemical Co PYRIDAZINE COMPOUND AND ITS USE
US7795258B2 (en) 2004-06-28 2010-09-14 Sumitomo Chemical Company, Limited Pyridazine compound and use thereof
PT1928454E (en) 2005-05-10 2014-12-04 Intermune Inc Pyridone derivatives for modulating stress-activated protein kinase system
CA2623813A1 (en) 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
BRPI0619516B1 (en) 2005-12-07 2015-09-15 Sumitomo Chemical Co pyridazine compound and its use, as well as plant disease control agent and method
DK1958948T3 (en) 2005-12-07 2011-10-31 Sumitomo Chemical Co Pyridazine compound and its use
DE102007008839A1 (en) 2007-02-23 2008-08-28 Bayer Healthcare Ag Process for the preparation of 4- (3-hydroxy-3-methylbutoxy) -5- [4- (methylsulfonyl) phenyl] -2-arylpyridazine-3 (2H) -ones
DE102007008840A1 (en) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Novel polymorphic form of 2- (4-fluorophenyl) -4-3-hydroxy-3-methyl-1-butoxy) -5- [4-methylsulphonyl) phenyl] -3 (2H) -pyridazinone (FHMP)
DE102007008843A1 (en) 2007-02-23 2008-08-28 Bayer Healthcare Ag Process for the preparation of 4,5-dihalo-2-aryl-2H-pyridazin-3-ones
DE102007020690A1 (en) * 2007-05-03 2008-11-06 Bayer Healthcare Ag New amorphous form of 2- (4-fluorophenyl) -4-3-hydroxy-3-methyl-1-butoxy) -6 [4-methylsulfonyl) phenyl] -3 (2H) -pyridazinone (FHMP)
DE102007020689A1 (en) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Novel polymorphic form of 2- (4-fluorophenyl) -4-3-hydroxy-3-methyl-1-butoxy-5- [4-methylsulfonyl) phenyl] 3 / 2H) -pyridazinone (FHMP)
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
JO3115B1 (en) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co Pyridazinone Compounds and Their Use as DAAO Inhibitors
JP6169492B2 (en) 2011-11-15 2017-07-26 武田薬品工業株式会社 Dihydroxy aromatic heterocyclic compounds
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
KR102373700B1 (en) 2014-04-02 2022-03-11 인터뮨, 인크. Anti-fibrotic pyridinones
US11096924B2 (en) 2016-09-07 2021-08-24 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and PGE2 antagonists
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009675A1 (en) * 1987-06-05 1988-12-15 Medicis Corporation Inhibition of arachidonic acid metabolism
AU691673B2 (en) * 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents

Also Published As

Publication number Publication date
SA98190764B1 (en) 2006-08-06
WO1999010331A1 (en) 1999-03-04
CO4970740A1 (en) 2000-11-07
EP1007515A1 (en) 2000-06-14
CA2299300A1 (en) 1999-03-04
ZA987555B (en) 1999-02-23
TWI232216B (en) 2005-05-11
CA2299300C (en) 2007-04-17

Similar Documents

Publication Publication Date Title
BR9812127A (en) Arylpyridazinones as inhibitors of prostaglein biosynthesis endoperoxide h synthase
BR9914858A (en) Prostaglandin endoperoxide biosynthesis inhibitors h
ATE319691T1 (en) PROSTAGLANDIN ENDOPEROXYDE H SYNTHASE BIOSYNTHESIS INHIBITORS
Grishanova et al. Aryl hydrocarbon receptor in oxidative stress as a double agent and its biological and therapeutic significance
Feldman et al. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
BRPI0011172B8 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
Kim et al. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
Ramalho et al. The search for new COX-2 inhibitors: a review of 2002–2008 patents
Rasooli et al. Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2
Osmaniye et al. Design, synthesis and biological evaluation of new N‐acyl hydrazones with a methyl sulfonyl moiety as selective COX‐2 inhibitors
Huguenin et al. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines
Thyagarajan et al. Acetylsalicylic acid inhibits the growth of melanoma tumors via SOX2-dependent-PAF-R-independent signaling pathway
Di Paolo et al. Exploring the activity of polyamine analogues on polyamine and spermine oxidase: Methoctramine, a potent and selective inhibitor of polyamine oxidase
Gao et al. NO-donating aspirin induces phase II enzymes in vitro and in vivo
Biava Introduction to COX inhibitors
Altinbay et al. Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing
Theoduloz et al. Inhibition of key enzymes in the inflammatory pathway by hybrid molecules of terpenes and synthetic drugs: In vitro and in silico studies
TR200000478T2 (en) Arylpyridazinones as inhibitors of prostaglandin endoperoxide H synthase biosynthesis.
Dammann Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity
Rowland et al. Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic,[3-(3, 4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2-(5H)-furanone], in multiple preclinical species
Réti et al. Enhancement of 5-fluorouracil efficacy on high COX-2 expressing HCA-7 cells by low dose indomethacin and NS-398 but not on low COX-2 expressing HT-29 cells
Berg et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells
Dudek et al. TR-FRET biochemical assays for detecting posttranslational modifications of p53
Gülcan et al. Marginally designed new profen analogues have the potential to inhibit cyclooxygenase enzymes
Licciardello et al. Targeting histone methylation: the development of selective methyltransferase and demethylase inhibitors

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE DIANTE DO QUE FOI EXPOSTO, OPINO POR NAO ACOLHER A PRESENTACAO DO INTERESSADO E, CONSIDERANDO QUE NAO FORAM APRESENTADOS ARGUMENTOS PERTINENTES, CONCLUI- SE QUE O PEDIDO EM LIDE NAO APRESENTA REQUISITOS QUE JUSTIFIQUEM O SEU REEXAME

B12B Appeal against refusal [chapter 12.2 patent gazette]